Press release
U.S. Liver Cancer Diagnostics Market to Reach USD 4.44 Billion by 2033, Fueled by Biomarker and AI Innovations
U.S. Liver Cancer Diagnostics Market
Ongoing developments in biomarker testing, liquid biopsy, and molecular diagnostics are enabling earlier and more accurate HCC detection. Advanced non-invasive technologies and multi-modal screening methods are replacing traditional imaging approaches, improving survival rates and expanding patient accessibility. North America, led by the United States, remains at the forefront due to robust R&D funding, FDA approvals, and integration of AI-driven diagnostic platforms.
Get a Free Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.datamintelligence.com/download-sample/liver-cancer-diagnostics-market?utm_source=OpenPR&utm_campaign=Onkar
Key Highlights from the Report
➤ Market poised to grow at 3.74% CAGR from 2025 to 2033.
➤ Estimated market value of USD 4.44 billion by 2033.
➤ FDA breakthroughs like Mursla Bio's EvoLiver and Siemens' ELF Test boost innovation.
➤ Biomarker-based blood tests outperform conventional ultrasound and AFP screening.
➤ AI-powered liquid biopsies and multi-omics diagnostics enhance early detection accuracy.
➤ Hospitals and diagnostic laboratories remain the dominant end-use segment.
Market Segmentation
The market is segmented by test type and end use. Laboratory tests, accounting for the largest revenue share (39.98% in 2024), include biomarker assays, immunoassays, and blood-based molecular diagnostics that are redefining early screening. The rise of multi-omics biomarkers and NGS-based tests has notably improved precision and sensitivity over traditional AFP-based assays.
In terms of end use, hospitals and diagnostic laboratories lead the market, representing over 49% share in 2024. Equipped with advanced imaging and molecular testing infrastructure, hospitals serve as the primary centers for early HCC diagnosis. Meanwhile, pharmaceutical companies and CROs are emerging as the fastest-growing users, advancing precision medicine, clinical trials, and AI-integrated testing solutions.
Regional Insights
The United States dominates the North American liver cancer diagnostics landscape, driven by FDA-backed innovations, NIH-funded trials, and cross-industry collaborations. Major studies like FUJIFILM's TRACER initiative and Exact Sciences' Oncoguard Liver test are transforming the standards of early detection with high sensitivity and specificity benchmarks.
Biotech advancements and healthcare investments are expanding access to AI-based liquid biopsies, integration of 3D histology, and digital pathology platforms, encouraging non-invasive and patient-centric diagnostic pathways. Favorable regulations and reimbursement support further strengthen the U.S. market's leadership in precision oncology diagnostics.
Get Customization in the Report as Per Your Business Requirements: https://www.datamintelligence.com/customize/liver-cancer-diagnostics-market?utm_source=OpenPR&utm_campaign=Onkar
Market Dynamics
Market Drivers
Increasing liver cancer prevalence, FDA breakthrough designations, and a strong emphasis on early HCC detection continue to propel growth. Integration of NGS, AI, and molecular biomarker testing is improving precision medicine and clinical decision-making across top-tier hospitals and labs.
Market Restraints
High costs, stringent regulatory pathways, and limited reimbursement for new diagnostic assays pose barriers to widespread adoption. Additionally, variability in diagnostic access across healthcare settings remains a challenge for uniform market growth.
Market Opportunities
Expanding R&D partnerships and AI-enabled biomarker algorithms open new avenues for early detection. Cost-effective and non-invasive testing methods, backed by strong clinical data, create opportunities for commercialization and scalable deployment across U.S. healthcare systems.
Reasons to Buy the Report
✔ Reliable forecast of the U.S. Liver Cancer Diagnostics Market (2025-2033) by DataM Intelligence.
✔ Detailed segmentation insights by test type and end user for strategic planning.
✔ Coverage of FDA breakthroughs and leading biomarker-based technology launches.
✔ Competitive profiling of top diagnostic and biotechnology players.
✔ In-depth analysis of trends shaping the future of non-invasive diagnostic innovations.
Purchase This Exclusive Report at Just USD 5455 Only: https://www.datamintelligence.com/buy-now-page?report=liver-cancer-diagnostics-market?utm_source=OpenPR&utm_campaign=Onkar
Frequently Asked Questions (FAQs)
◆ How big is the U.S. Liver Cancer Diagnostics Market in 2025?
◆ What is the projected growth rate of the U.S. Liver Cancer Diagnostics Market through 2033?
◆ Which test type dominates liver cancer diagnostics in the United States?
◆ Who are the key players leading the U.S. Liver Cancer Diagnostics market landscape?
◆ How are AI and liquid biopsy technologies transforming early HCC detection?
Company Insights
Abbott Laboratories
Thermo Fisher Scientific, Inc.
F. Hoffmann-La Roche Ltd.
Qiagen N.V.
Siemens Healthineers
Becton, Dickinson & Company
Illumina, Inc.
Epigenomics AG
Koninklijke Philips N.V.
Fujifilm Medical Systems U.S.A., Inc.
Recent Developments
January 2025: The FDA granted breakthrough device designation to Mursla Bio's EvoLiver Test for HCC surveillance, marking a new era in non-invasive liver cancer diagnostics.
October 2024: Hoag Hospital introduced the Edison Histotripsy System, a robotic ultrasound-based tumor destruction technology - the first FDA-approved non-invasive therapy for liver tumors.
Conclusion
The U.S. Liver Cancer Diagnostics Market is at the forefront of a transformation driven by biomarker science, FDA-approved liquid biopsies, and AI-assisted analytics. With breakthroughs accelerating early HCC detection and precision medicine adoption, the industry is redefining clinical pathways for one of the most lethal cancers. Ongoing collaborations between research institutions, biotech innovators, and healthcare providers are set to enhance accessibility, accuracy, and patient outcomes, securing the United States' leadership in next-generation cancer diagnostics.
Contact Us
Mr. Sai Kiran
DataM Intelligence 4market Research LLP Ground floor
DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com
About Us
DataM Intelligence 4Market Research is a comprehensive market intelligence platform offering syndicated and customized reports along with expert consulting across multiple industries, including chemicals, healthcare, agriculture, food & beverages, and more. With extensive experience and a strategy-focused approach, DataM provides businesses and individuals with reliable market insights, statistical forecasts, and personalized research solutions to help them make informed decisions and successfully bring innovations to market.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release U.S. Liver Cancer Diagnostics Market to Reach USD 4.44 Billion by 2033, Fueled by Biomarker and AI Innovations here
News-ID: 4223274 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
U.S. Stem Cell Therapy Market to Surge to USD 19.54 Billion by 2034 at 12.55% CA …
The U.S. Stem Cell Therapy Market is entering a high-growth phase, with its size estimated at USD 5.99 billion in 2024 and projected to reach USD 19.54 billion by 2034, according to DataM Intelligence. Driven by a rising incidence of chronic illnesses such as cancer, diabetes, neurological disorders, and musculoskeletal problems, demand for advanced regenerative solutions is expanding rapidly. Stem cell therapies are gaining traction due to their ability to…
US Industrial Valve Market Set to Reach USD 21.5 Billion by 2035, Driven by Auto …
The US Industrial Valve Market is witnessing substantial growth momentum, valued at USD 12.5 billion in 2024 and projected to reach USD 21.5 billion by 2035, according to DataM Intelligence. Registering a CAGR of 5.05% between 2025 and 2035, the market is buoyed by increasing demand from sectors such as oil and gas, power generation, water management, and manufacturing.
Expanding infrastructure projects, coupled with the widespread adoption of automation technologies, are…
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market Expands with A …
Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market is valued at a significant CAGR during the forecast period (2024-2031). As per DataM Intelligence Database.
Non-Alcoholic Steatohepatitis (NASH) therapeutics and diagnostics focus on managing liver inflammation and fibrosis caused by fat accumulation. Diagnostic tools include imaging, liver biopsy, and biomarker assays. Current treatments target metabolic pathways, insulin resistance, and inflammation. Drugs under development include FXR agonists, PPAR modulators, and anti-fibrotic agents. Lifestyle changes remain…
U.S. Precision Farming Market to Reach $4.5 Billion by 2030 Leveraging IoT and A …
The U.S. precision farming market is witnessing robust growth driven by the increasing adoption of Internet of Things (IoT) technologies and advanced analytics that optimize farming inputs, labor, and costs in sustainable agricultural practices. DataM Intelligence estimates the market at USD 2.62 billion in 2023, with a projected CAGR of 9.5% from 2024 to 2030, positioning the U.S. as a major global precision farming hub with nearly 25% market share…
More Releases for Liver
Rising Liver Disease Cases Drive Growth In Liver Metastases Treatment Market Dri …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Liver Metastases Treatment Market Size By 2025?
The market for treating liver metastases has seen significant growth in the past few years. It is projected to increase from $1.57 billion in 2024 to $1.71 billion in 2025, with a compound annual growth rate (CAGR) of…
LivCare Liver Support
The liver plays a crucial role in maintaining overall well-being, performing essential functions like detoxification, digestion, and metabolism. However, many people overlook the importance of liver health until problems arise. LivCare Liver Support is a premium supplement designed to keep your liver in peak condition. By incorporating this supplement into your daily routine, you can help ensure your liver functions optimally, leading to better overall health.
● Product Name - LivCare…
Liver Cancer Therapeutics Market - Empowering Recovery, Restoring Health: Innova …
Newark, New Castle, USA - new report, titled Liver Cancer Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Liver Cancer Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Liver Cancer Therapeutics market. The report offers an overview of…
Liver Health Supplements Market Grows Strong as Consumers Adopt Proactive Measur …
Global liver health supplements market was valued at US$ 8.7 Bn in 2021, is growing at an estimated CAGR of 5.8% over the forecast period (2022 - 2030). The liver health supplements market is growing due to the increasing awareness of the importance of liver health and the rise of lifestyle-related liver diseases. The market offers a wide range of supplements that help in improving liver function, supporting liver detoxification,…
Urgent Liver 911 Reviews 2021: Is Urgent Liver 911 Legit?
Urgent Liver 911 by PhytAge Laboratories is a powerful diet that promotes liver function by combining natural minerals and nutrients. The diet is made up of plant and herbal extracts that collectively aid in liver cell protection. While the liver is an important human organ that promotes general health and vitality, most people are unaware that even those who appear to be in good health can be affected by liver…
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production…
